Zach Taiji Docs

Search

SearchSearch

Grail & Galleri Social Listening Reports

Oct 12, 202375 min read

Share of Voice Overview

Reporting DateExact SciencesGrail and GalleriGuardantInvitaeIoniqNatera
2023-04-1367182507
2023-04-2066311101
2023-05-0513821312
2023-05-1133558511
2023-05-183016329123
2023-05-25551220804
2023-06-0117128211
2023-06-08
2023-06-152876114
2023-06-222931311
2023-06-29132184902
2023-07-131991111
2023-07-2016613301
2023-07-271253155114
2023-08-034028177111
2023-08-10294716305
2023-08-1742465501
2023-08-242943125011
2023-08-31372918907
2023-09-08322235408
2023-09-144315265011
2023-09-212936147012
2023-09-283136211004
2023-10-05263782613
2023-10-1219677601
2023-10-20225061507
2023-10-26542414405
2023-11-022422259020
2023-11-0935162612011
2023-11-16371736406
2023-11-302930187015
2024-03-013637123013
2024-04-0427644104
2024-04-114724181010
2024-04-18433313407
2024-04-253327177016
2024-05-02353577016

Weekly Reports

May 02, 2024

Hello team, Please find our social listening snapshot below for 4/26 - 5/2.

Grail, Galleri, and Illumina

  • Our share of voice increased by 8%.
  • The Galleri Test:
    • An article for The Atlantic debates the benefits of Galleri and similar multi-cancer blood tests, as they are not yet fully endorsed or approved by medical authorities. The article mentions that clinical trials are still ongoing to determine if MCED tests can actually save lives.
    • On Reddit, a patient receives a $900 bill for the Galleri test after their doctor ordered it without consent. HCPs and medical professionals comment that the patient should report their doctor for fraud to the medical board and insurance company. In a separate thread in r/Oncology, the aforementioned issue is discussed and individuals criticize the Galleri test.
    • On X, an HCP tours the GRAIL lab and offer the Galleri test to his patients.
    • OCI Insurance conducts a webinar about the Galleri test and the value it brings to life insurance sales.
    • On LinkedIn, the CEO of John Hancock publishes an article about MCED testing and Galleri test, noting that John Hancock was the first life insurance carrier to offer eligible life insurance customers access to the Galleri test.
    • Ahead of Mother’s Day and National Women’s Health Month, Colorado Integrative Healthcare promotes their offering of the Galleri test to patients on Instagram.
    • The Northern Cancer Alliance reminds NHS-Galleri trial participants to return to the mobile clinic for their last blood samples, on X.
  • Illumina:
    • The FTC is receiving more complaints about healthcare companies abusing their market power to raise prices and reduce service; the Illumina-FTC case is mentioned in this article about the issue on MedPage Today.

Companies We Follow

  • Exact Sciences:
    • Exact Sciences publishes its 2023 ESG report.
    • On Reddit, Cologuard users continue to stress the importance of getting a colonoscopy after testing positive.
    • On X, users joke about Cologuard employees.
    • Exact Sciences achieves a 45% containment rate with its contact center system, in a case study published by Five9.
  • Guardant Health:
    • Guardant’s Co-CEO and Founder, Helmy Eltoukhy, discusses the role of liquid biopsies in closing the gap in cancer care.
    • The Biden Cancer Moonshot announces that Guardant Health will step up with actions to advance colorectal cancer awareness and screening in vulnerable communities.
  • Natera:
  • Invitae:

April 25, 2024

Hello team, Please find our social listening snapshot below for 4/19 - 4/25.

Grail, Galleri, and Illumina

  • Our share of voice was 27%.
  • The Galleri Test:
  • Galleri Classic:
    • In Golf Monthly, Hall of Famer Juli Inkster discusses her partnership with GRAIL for the Galleri Classic and her goals to raise awareness about early cancer detection.
    • In an Op-Ed for Essentially Sports, the Golf Channel’s decision to air the Galleri Classic over the Ford Championship is criticized.

Companies We Follow

  • Exact Sciences:
    • Exact Sciences hosts its Annual Employee Awards ceremony, and shares a photo to Facebook.
    • On Instagram, HCPs partner for a MedEd video about the Cologuard test.
    • On Reddit, patients suggest getting a colonoscopy over the Cologuard test due to false positives. On X, HCPs debate colonoscopy vs the Cologuard test, with one person mentioning the increased accessibility/access the Cologuard test provides.
  • Guardant Health:
    • Guardant Health hosts a webinar exploring the current and future state of lung cancer care, in partnership with the Lung Cancer Policy Network.
    • Guardant Health chooses OHMX.bio as their trusted partner to leverage their Health Infinity platform and investigate its bimodal readout towards ADC (antibody-drug conjugate) and HRD (homologous recombinant deficiency).
    • The FDA Advisory Panel’s review of the Shield blood test to screen for colorectal cancer will be held on May 23rd.
  • Natera:
    • Natera’s VP of Operations will speak at the 29th Annual Executive War College on Laboratory and Pathology Management.
    • Natera reaches a milestone of more than 200 peer-reviewed publications highlighting the company’s technology in the scientific literature.
  • Invitae:

April 18, 2024

Hello team, Please find our social listening snapshot below for 4/12 - 4/18.

Grail, Galleri, and Illumina

  • Our share of voice increased by 9%.
  • The Galleri Test:
    • The Washington Post publishes an article about MCED tests, highlighting a Galleri test patient case and data from the Galleri study. Costs of other tests are discussed, including Guardant Health’s Shield and Exact Sciences’ Cancerguard. The Washington Times publishes a similar article.
    • In a Case Report published on Nature.com, the Galleri test is mentioned as a test that uses machine learning to detect cancer signals across multiple cancer types.
    • Clinics promote their of the Galleri test (1, 2).
    • Dr Kathy Miller discusses the potential mismatch between results and conclusions from the PATHFINDER study for Medscape.
    • An individual visits a Galleri test testing site in North Carolina, sharing photos on LinkedIn.
  • Illumina:

Companies We Follow

  • Exact Sciences:
    • Katie Couric posts a video about the Cologuard classic on X.
    • An HCP recommends skipping the Cologuard test and going straight to a colonscopy.
    • An online provider compares the Cologuard test to a colonscopy.
  • Guardant Health:
    • Guardant’s Shield test is included in the aforementioned Washington Post and Washington Times articles. No other major news was identified this week.
  • Natera:
    • A stage IV male breast cancer patient on Instagram uses Natera’s Signatera test to track tumors early. A gynecologist takes the test as well.
    • The NCTN has teamed with Natera to use biomarkers in a study focused on muscle-invasive urothelial cancer (MIUC).
  • Invitae:
    • Invitae exhibits at the Attending City of Hope Clinical Cancer Genomics Conference.
    • On Reddit, individuals mention using Invitae’s genetic testing.

April 11, 2024

Hello team, Please find our social listening snapshot below for 4/5 - 4/11.

Grail, Galleri, and Illumina

  • Our share of voice was 24%.
  • Grail:
    • WHO scientists question GRAIL’s plan for evaluating its multi-cancer Galleri blood test.
    • GRAIL’s Dr. Eric Klein joins Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities, on the ReachMD Podcast.
    • AtAACR24, BLOODPAC and panelists from Natera, GRAIL, the NCI, Guardant, Friends of Cancer Research and Dana Farber discuss risk assessment in liquid biopsy for early cancer detection.
  • The Galleri Test:
    • Iron Chef Cat Cora promotes taking the galleri test on Instagram, receiving nearly 250 engagements.
    • The bay area offers the Galleri test for free as part of Sutter Health and the Palo Alto Medical Foundation’s (PAMF) participation in the Pathfinder 2 study, in an article published on InMenlo.
    • On LinkedIn, Texas Medical & Wellness Clinic announces availability of the Galleri test. An HCP advocates for the test.
  • Illumina:
    • Barrons reports on the MCED landscape competition between GRAIL and Exact Sciences, despite the Illumina-Grail divestment.
    • Illumina announces itsACCR24 presence on LinkedIn, accompanied by a poster presentation on RNA-Seq data on snoRNAs and their influence on cancer and plasticity phenotypes.
  • Galleri Classic:

Companies We Follow

April 04, 2024

Make sure to check LinkedIn and TikTok manually and add into reporting.

Use this saved Netbase analysis to go through posts

Hello team, Please find our social listening snapshot below for 3/27 - 4/4.

Grail, Galleri, and Illumina

  • Our share of voice was 64%—with nearly half of our total SOV about the Galleri Classic.
  • Galleri Classic Highlights:
    • Athlete Greg Chalmers has an enjoyable experience competing in the event; in a post on X (117K views) he mentions @GalleriClassic. A golfing analyst mentions both accounts in a post on X.
    • PGA Tour Champions publishes highlights from round 2 of the Galleri Classic on YouTube. One of their posts on X, mentioning @GalleriClassic, receives 92.7k views and 525 engagements. Their post announcing Retief Goosen as the winner receives 89.7k views and 230+ engagements.
    • On Instagram, sponsors, fans, and attendees post photos and videos during the Galleri Classic (1, 2, 3, 4, 5).
    • On LinkedIn, John Hancock offers the Galleri test through its Vitality Program, in a post featuring commentary from golfer and Galleri Classic participant, Ernie Els. Individuals and sponsors share photos from the event to the platform (1, 2, 3, 4)
  • GRAIL:
  • The Galleri Test:
    • On Instagram, Dr. Eleonora Teplinsky of the Valley Breast Center in NJ discusses the Galleri test to coincide with National Cancer Prevention and Early Detection Month—including an overview of the test, PATHFINDER study data, and FDA status. Her overall summary of the test is “promising, but not ready for prime time”. She also posts the video on her YouTube channel, TikTok, and LinkedIn.
    • Other providers promote the Galleri test in posts on Instagram (1, 2, 3, 4).
    • On LinkedIn, Becker’s Healthcare shares a case study highlighting the partnership between Indianapolis-based Community Health Network and GRAIL for the Galleri test.

Companies We Follow

  • Exact Sciences:
    • Mayo Clinic health care professionals talk about the importance of colorectal cancer screening, including the Cologuard test, in a video on YouTube.
    • ForColorectalCancerAwarenessMonth, Fight Colorectal Cancer recognizes its sponsors, including Exact Sciences, Guardant, and Natera, on Instagram.
    • A career investigator from The Stand up to Cancer organization’s colorectal cancer team advocates for early cancer detection in a short video. The team is supported by Exact Sciences.
  • Guardant Health:
    • The Royal Marsden NHS Foundation Trust highlights its new liquid biopsy test, developed by Guardant, on Instagram.
    • Guardant sponsors the Colon Cancer Coalition’s 2024 Great Colon Tour with Bayer.
  • Natera:
  • Invitae:

March 01, 2024

Hello team, Please find our social listening snapshot below for 2/23 - 2/29.

Grail, Galleri, and Illumina

  • Our share of voice was 37%.
  • Grail:
  • The Galleri Test:
    • A case study published in Becker’s Hospital Review describes how Indiana’s Community Health Network thoroughly vetted the Galleri test clinically and financially before implementing it systemwide.
    • An independent outlet based in the UK covers the Galleri-NHS trials, reporting that widespread availability of the Galleri test on the NHS could still be years away as more evaluation is needed.
    • The Woodland Wellness Clinic (Texas) advocates for the Galleri test in a promotional post for Cancer Prevention Month on Instagram. Another Texas-based provider hosts an open house offering the Galleri test. A Missouri-based provider promotes an online quiz to help individuals determine if they qualify for the Galleri test.
    • In a Reddit thread, users discuss the Galleri test. One person reports taking the test every 18 months, while another person is advised by their doctor not to take the test because of false positives and negatives.
  • Galleri Classic:
    • Contenders and sponsors for the upcoming Galleri Classic are announced in press releases, with coverage in Golf publications (1, 2, 3)

Companies We Follow

  • Exact Sciences:
    • GoGo Cologuard, a endless runner video game from Exact Sciences, is released along with a trailer for the game on YouTube.
    • An MD from Exact Sciences discusses the significance of the ECOG-ACRIN E4112 and ADAPTcycle clinical trials, highlighting their role in individualizing breast cancer treatment decisions.
    • Exact Sciences sponsors a Latino Cancer Patient Advocate Training Program.
    • A studio engineer for a podcast receives an unsolicited shipment of Cologuard; the podcast’s host reports.
  • Guardant Health:
    • Ahead of Colorectal Cancer Awareness Month, A CBS affiliate in Idaho airs a segment highlighting The Shield™ test from Guardant Health, a new test that screens for colorectal cancer. An accompanying survey conducted by Harris Poll finds that “93% of primary care physicians said the largest barrier to patients completing their screening is how unpleasant colonoscopies are”.
    • Guardant Health sponsors the 8th Annual Liquid Biopsy for Precision Oncology Summit.
  • Natera:
    • Natera’s Signatera MRD test is now covered by Medicare for ovarian and neoadjuvant breast cancer.
    • On Reddit, a patient puts an ask out for oncologists who will offer the Signatera ctDNA test.
  • Invitae:

November 30, 2023

Hello team, Please find our social listening snapshot below for 11/24 - 11/30.

Grail, Galleri, and Illumina

Companies We Follow

  • Exact Sciences:
    • Exact Sciences partners with WayForward for a food donation drive, in a post on Instagram.
    • On Reddit, users share their experiences with taking the Cologuard test.
    • On LinkedIn, Exact Sciences KOLs meet to discuss strategy for the APAC region.
    • An article on Yahoo! Finance reviews Exact Sciences’ financial performance from over the last decade, highlighting its screening tests.
  • Guardant Health:
    • Guardant Health highlights upcoming presentations using its tests, ahead of the ESMO Asia Conference, in a post on X.
    • A press release is published ahead of the San Antonio Breast Cancer Symposium, announcing upcoming Guardant presentations for its PlasmaMATCH, SOLTI-1903 HOPE, and PRAEGNANT studies.
  • Natera:
    • On Instagram, a patient shares an experience with the Signatera test.
    • Mridula George, MD discusses The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients, including the Signatera test.
    • Data from the RenaCARE study highlights how genetic testing can help address critical limitations in the current approach to diagnosing chronic kidney disease.
  • Invitae:
    • On Reddit, a patient completes their Invitae Cancer panel, asking the community about the difference between somatic and germline testing.
    • A clinical geneticist for Invitae shares results from a study evaluating germline genetic testing (GGT) for patients with lung cancer, on LinkedIn.

November 16, 2023

Hello team, Please find our social listening snapshot below for 11/10 - 11/16.

Grail, Galleri, and Illumina

  • Our share of voice was 17%.
  • An article in Interesting Engineering highlights the work that the Centre for Novostics in Hong Kong is doing to develop a low-cost $50 version of the Galleri test. TechTimes also covers the news.
  • Grail’s partnership with fire departments in both Virginia Beach and Chesapeake to provide the Galleri test to its firefighters is highlighted in 13 News Now, an ABC affiliate. On LinkedIn, Grail employees promote.
  • Renal & Urology News shares results from the PATHFINDER study: “Time to Cancer Diagnosis After MCED Testing in Asymptomatic Patients”.
  • On Instagram, a Texas-based provider promotes its offering of the Galleri test to its patients. Optimal Medical Group promotes its upcoming screening event featuring the Galleri test.
  • Grail’s Head of Marketing shares a photo to LinkedIn taken from the 20th Anniversary Hanson House Foundation fundraiser in Palm Springs.
  • Dr. Joel Kahn highlights a statistic claiming that “70% of people who die of cancer, die because there is no routine screening available for their cancer”. In the caption, he promotes the Galleri test as a solution.
  • On Reddit, a conversation in the main pancreatic cancer subreddit mentions the Galleri test as a solution. Another patient in the subreddit receives a negative Galleri test result, but questions its accuracy.

Companies We Follow

  • Exact Sciences:
  • Guardant Health:
    • Reuters reports on TwinStrand Biosciences’s patent lawsuit against Guardant, awarding TwinStrand $84.3 million.
    • In South Korea, Guardant launches a blood-based screening test for colorectal cancer, called Shield, as reported by BioSpectrum Asia.
    • Guardant’s CIO participates in a panel at Menlo Ventures’ CxO summit, with a post promoted on LinkedIn.
  • Natera:
    • The European Organisation for Research and Treatment of Cancer (EORTC) partners with Natera and Menarini for phase III of the TREAT ctDNA trial.
    • Natera and Merck partner on real-world data collaboration—Merck will utilize Natera’s real-world database to advance oncology research, as reported by Contract Pharma. Natera also publishes a post about the partnership on X.
  • Invitae:
    • On Reddit, a user shares a positive experience with Invitae’s genetic testing. Other users recommend Invitae’s genetic testing in discussions (1,2, 3).
    • Invitae participates in a panel atSEQCEQ23, in a photo shared to X. In another post, Invitae’s Clinical Geneticist continues to promote Invitae’s Common Hereditary Cancers Panel.

November 09, 2023

Hello team, Please find our social listening snapshot below for 11/3 - 11/9.

Grail, Galleri, and Illumina

  • Our share of voice was 16%.
  • Grail:
    • Grail’s VP of Clinical Development, Dr. Eric Fung, is interviewed by the Finding Genius Podcast; the podcast promotes on Instagram and YouTube Shorts.
    • On LinkedIn, a Grail employee celebrates the increased awareness of the Galleri test , resulting from presence at industry conferences throughout the year.
  • The Galleri Test:
    • The Galleri test is discussed on Patient Care’s video series, The Role of the Primary Care Physician in Early Cancer Detection with Blood-Based Screening: “There’s just one test currently on the market that’s available as a true liquid biopsy and preventive care and screening for cancer. And that is the Galleri test from GRAIL. This is a blood biopsy test that looks at over 50 different cancers with one blood draw.” (Episode 4: Landscape of Multi-Cancer Early Detection Tests)
    • CA, the official cancer journal of the American Cancer Society, shares findings from the recent SYMPLIFY study in its latest issue.
    • A new integrative and regenerative medicine clinic in Houston, Texas opens; an article on The Leader reports on the opening and mentions the Galleri test as part of the clinic’s offered services.
  • Galleri Classic:

Companies We Follow

November 02, 2023

Hello team, Please find our social listening snapshot below for 10/26 - 11/2.

Grail, Galleri, and Illumina

  • Our share of voice was 22%.
  • Grail:
  • The Galleri Test:
  • Illumina:
    • In an Op-Ed for Forbes, the FTC’s battle with Illumina is discussed within a broader conversation that challenges the FTC to rethink how they approach anti-trust and consumer protection law.

Companies We Follow

  • Exact Sciences:
    • The company announces its strong Q3 earnings on Facebook, as well as 2023-24 Exact Sciences sponsored athletes at the University of Wisconsin-Madison. On X, the Director of NIL Strategy for the Wisconsin Badgers also shares the sponsored athletes announcement.
    • On Reddit, users share their experiences in taking the Oncotype DX test. Another user shares how Exact Sciences’ financial assistance program helped them cover costs.
    • The Cologuard test is recommended in a lengthy discussion on Hackernews about the value of colonoscopies. Grail is also mentioned in the discussion.
  • Guardant Health:
  • Natera:
  • Invitae:

October 26, 2023

Make sure to check LinkedIn and TikTok manually and add into reporting.

Hello team, Please find our social listening snapshot below for 10/21 - 10/26.

Grail, Galleri, and Illumina

  • Our share of voice was 24%.
  • Grail:
    • On X, an HCP shares Grail’s placement on Fortune’s 2023 Change the World List for the Galleri test.
    • The Messenger publishes an article highlighting recent data from the PATHFINDER study.
  • The Galleri Test:
    • WSJ publishes a full story on the Galleri test. While doctors and researchers are excited by its potential for early cancer detection, there is disagreement about whether patients should use it yet. The article suggest that more data is still needed on its effectiveness before widespread patient use is recommended. An HCP on LinkedIn shares the article with mixed feedback in the comments.
    • A webinar on the landscape of MCED occurs on Patient Care, where the Galleri test is mentioned as the only test on the market available as “a true liquid biopsy” solution.
    • On Instagram, provider Vitalife promotes the Galleri test in conjunction withBreastCancerAwarenessMonth. Dr. Renee Young for the Young Wellness Center continues promoting Galleri test blood draws days with a Halloween theme. The Magaziner Center for Wellnes, based out of Philadelphia, shares a video highlighting a quote from Dr. Magaziner about the Galleri test.
  • Illumina:
    • An Op-Ed about the FTC’s Lina Kahn is published in NewsMax, an independent publication. The FTC-Illumina battle is mentioned within.

Companies We Follow

October 20, 2023

Hello team, Please find our social listening snapshot below for 10/13 - 10/20.

Grail, Galleri, and Illumina

Companies We Follow

  • Exact Sciences:
  • Guardant Health:
    • An informational patient video is created for The Shield cancer screening test and published on Youtube.
    • On LinkedIn, news of Guardant’s plans to accelerate development of new cancer therapies in China is shared.
  • Natera:
    • Natera’s ongoing patent infringement lawsuit against Invitae is covered by Bloomberg Law—with Invitae asking a judge to toss Natera’s $19M patent verdict against ArcherDx. Natera’s director of ESG and sustainability will speak at the 2023 B:Civic Summit, promoted in a post on X.
  • Invitae:

October 12, 2023

Hello team, Please find our social listening snapshot below for 10/6 - 10/12.

Grail, Galleri, and Illumina

  • Our share of voice increased by 30%, with the PATHFINDER 1 study being a discussion driver among the media, providers, HCPs, and individuals:
    • MedPage Today outlines how the cancer screening testing process would play out in the clinic, supported by findings from the PATHFINDER 1 study.
    • Provider Sutter Health publishes the study findings on its blog, along with a Galleri test patient story for Louis “Lou” Sall.
    • HCP and members of the media share key findings and graphics from the study on X (1, 2, 3).
    • On LinkedIn, the study is met with skepticism by a user (1, 2).
  • Grail:
    • Precede Biosciences’ liquid biopsy platform and its research is covered by MedCity News as the company exits stealth mode; Grail, Exact Sciences, Guardant, and Roche are cited in the article as key players in the MCED and liquid biopsy spaces.
    • On LinkedIn, Grail employees promote the Galleri booth atHLTH2023 (1, 2)
  • The Galleri Test:
    • On Instagram, an HCP promotes the Galleri test, mentioning her father’s early cancer diagnosis from taking the test. Magaziner Center for Wellness posts a video highlighting the Galleri test as the provider announces the availability of the test to its patients.
    • On LinkedIn, MassMutual employees promote its offering of the Galleri test to its policyholders.
  • Illumina:

Companies We Follow

October 05, 2023

Hello team, Please find our competitive social listening snapshot below for 9/29 - 10/5.

Grail, Galleri, and Illumina

  • Our share of voice increased 1%. Grail is included in Fortune’s ‘Change the World’ list, covered in Insurtech Insights, and on LinkedIn, employees share photos from the Grail booth at the 69th Annual IFEBP Conference.
  • HCPs and providers promote the Galleri test as part of their services:
    • A patient story is featured in the Herald Community Newspaper. 54-year old Valerie used the Galleri test to diagnose her cancer before any symptoms.
    • On LinkedIn, an HCP promotes the Galleri test for Breast Cancer Awareness Month.
    • On TikTok, Dr. Becky Lynn educates viewers on how the Galleri test helps screen for 50 different types of cancer.
    • Accarent Health makes the Galleri test available to its patients, announced via press release. Its president comments, “Accarent Health is thrilled to offer the Galleri test by GRAIL, a pioneer in early cancer detection technology. This new offering represents another pivotal step in our mission to provide comprehensive, transparent, bundled, quality, and cost-effective cancer pathways for the nation’s self-insured employers and their employees.”
    • On YouTube, provider Executive Health promotes the Galleri test via a YouTube Short.
    • On Instagram, Dr. Weimin Hu promotes her upcoming lecture about skin health and skin cancer prevention, which will feature the Galleri test. Myra Reed, MD, shares an Instagram video about Ovarian cancer early detection, offering the Galleri test as a screening solution. A Nurse for Synergy Health Advisors mentions the Galleri test in a post promoting her upcoming Fall Open House.

Companies We Follow

September 28, 2023

Hello team, Please find our competitive social listening snapshot below for 9/22 - 9/28.

Grail, Galleri, and Illumina

  • Our share of voice remained at 36%, with discussions from providers, NHS collaborators, and industry media.
  • The Greater Manchester Integrated Care Partnership posts a blog about the NHS-Galleri trial, highlighting the enrollment of 140k volunteers from across England, including 20k from Greater Manchester.
  • Providers on Instagram promote the Galleri test:
    • truMD highlights its three innovative healthcare solutions, including its offering of the Galleri test. The post highlights the test’s “aim to help individuals identify potential health risks before they escalate”.
    • MetaboLabs highlights its Advanced Cancer Screening service, comprised of the Galleri test. The post underscores the importance of early detection and prevention in cancer, and how the Galleri test is making this possible.
  • On Reddit, an “Explain Like I’m Five” question asks what makes pancreatic cancer so deadly in comparison to other cancers. An HCP comments that one of their patients has already received a false negative from the Galleri test. Another thread on r/cancer (that is now deleted by the original poster) references Galleri test specificity and sensitivity statistics.
  • Illumina hires Jacob Thaysen as its new CEO, as reported by Rama on Healthcare. The article mentions Illumina’s proxy battle with billionaire investor Carl Icahn. An article from Medical Product Outsourcing emphasizes the critical role of regulatory bodies in shaping the healthcare industry—and references Illumina’s recent challenges with the FTC and EU.

Companies We Follow

  • An article on the Investor Times discusses the frequency with which Medicare covers the cost of Exact Sciences’ Cologuard tests, providing information on the eligibility criteria for Medicare coverage. U.S. News & World Report ranked the top 58 healthcare companies to work for, based on publicly available employee sentiment and other data; Illumina and Exact Sciences are included in the rankings. On Reddit, several posts highlight the complexities and challenges patients face when the Oncotype and Cologuard tests are used, from insurance coverage issues to medical treatment decisions (1, 2, 3, 4, 5, 6).
  • Simranjit Singh, CEO of Guardant Health, discusses how the Human Genome Project has affected Healthcare in a conversation with Asia’s Change Makers on YouTube. Patients on X discuss timing for Guardant 360 DNA testing. One patient complains about a false positive test result.
  • On YouTube, a cancer influencer shares his Signatera (Natera) test results in a patient journey update. On Reddit, patients discuss the Signatera ctDNA test in r/cancer. Other Reddit discussions include insurance and billing concerns (1, 2).
  • Invitae’s genetic testing is mentioned in a post for National Previvor Day on Instagram. On X, the company promotes Prostate Awareness Month.

September 21, 2023

Hello team, Please find our competitive social listening snapshot below for 9/15 - 9/21.

Grail, Galleri, and Illumina

  • Our share of voice increased by 21%.
  • The Galleri test is discussed by providers, advocacy groups, patients, and government:
    • A YouTube video by Mark Hyman, MD, for provider Function Health, highlights the Galleri test—offering it nearly at cost to patients to increase accessibility.
    • An Instagram post from military veteran support organization HunterSeven Foundation advocates for the importance of early cancer detection ahead of its Integrative Warrior Health Summit, and suggests that adding the Galleri test to recommended cancer screenings could help in treating cancer at a more manageable stage. The organization will offer blood draws during the event.
    • Mayo Clinic’s recognition of the Galleri test is mentioned in a cancer discussion on Reddit. Another discussion on r/pancreaticcancer about genetic testing mentions both the IMMRay pancan-d test and the Galleri test as solutions.
    • The Oldham Care Organisation shares a photo on X to promote the return of the NHS-Galleri trial to Oldham.
  • The EU’s fine of Illumina is referenced in an article about antitrust activity in medtech.
  • The Galleri Classic is mentioned in an article on Golfweek about Professional golfer John Daly .

Companies We Follow

  • Most discussions about Exact Sciences over the last week took place on Reddit, as patients discuss the limitations and experiences with the Cologuard test. Skepticism regarding false positives causes some patients emotional and financial strain—with some of the comments advocating for colonoscopy as a more accurate, albeit more invasive, screening method. (1, 2, 3, 4, 5, 6, 7, 8)
  • Guardant Health is mentioned in a post on X about an upcoming NHS Cancer Programme networking event. The company is also included in a Liquid Biopsy market report.
  • Natera expands its leadership team. Pricing for Natera’s Panorama test is outlined in a blog, likely an SEO effort. The American Association of Kidney Patients promotes Natera as a gold sponsor to its 48th Annual National Patient Meeting.
  • Invitae receives a “Top 10 most important things you need to know” sponsored article from DotCom magazine. On Reddit, Invitae Genetic Testing is discussed in various contexts, from its role in diagnosing complex conditions like EDS and POTS to its utility in prenatal screening and cancer risk assessment. There are questions about the potential for false results or tampering. Invitae is contrasted positively against consumer genetics tests like 23&Me. (1, 2, 3, 4, 5, 6)

September 14, 2023

Hello team, Please find our competitive social listening snapshot below for 9/9 - 9/14.

Grail, Galleri, and Illumina

Companies We Follow

Additional Commentary

Publications continue reporting on JAMA’s cancer screening meta-analysis published in late August:

September 08, 2023

Hello team, Please find our competitive social listening snapshot below for 9/1 - 9/8.

Grail, Galleri, and Illumina

Companies We Follow

  • Exact Sciences’ recent facility tour with Jill Biden is promoted on the company’s Facebook. Local NBC affiliate, WMTV, publishes a broadcast segment about her visit. A provider on Instagram, Athens OBGYN, promotes the Oncotype DX test.
  • Guardant Health’s AMEA CEO discusses conquering cancer in a podcast featuring change-makers in Asia. An article in InvesBrain highlights advances and challenges in the liquid biopsy field, with commentary from Guardant’s associate director of bioinformatics discussing the benefits of the Guardant Infinity platform.
  • A cancer patient promotes Natera’s Signatera testing on Instagram, sharing that her cancer results have shrunk by 300%. In r/breastcancer on Reddit, a patient mentions the Signatera test. An individual on X negatively comments about the company’s monopoly on prenatal genetic testing.
  • On Reddit, patients discuss Invitae’s genetic testing in several threads (1, 2, 3). Lumea and Invitae partner to advance access to genetic testing.

Additional Commentary

Several publications report on JAMA’s cancer screening meta-analysis published in late August:

  • CNN Health’s story puts the emphasis on commentary from the researchers stating that cancer screen should not be abandoned. Additional commentary from researchers underlines the importance of large-scale studies like these to better understand how the benefits compare to the costs of screening.
  • STAT criticizes the math behind the report and the researcher’s summary that “despite the popular tagline, most cancer screening does not save lives”—with opinion that cancer screening is not so black and white, and that cancer screening should be assessed in terms of its ability to improve the health of populations.
  • JUTA Medical Brief publishes a summary of the report and includes mentions of the coverage from CNN.

August 31, 2023

Hello team, Please find our competitive social listening snapshot below for 8/25 - 8/31.

Grail, Galleri, and Illumina

Companies We Follow

August 24, 2023

Hello team, Please find our competitive social listening snapshot below for 8/18 - 8/24.

Grail, Galleri, and Illumina

Companies We Follow

August 17, 2023

Hello team, Please find our competitive social listening snapshot below for 8/10 - 8/17.

Grail, Galleri, and Illumina

Companies We Follow

August 10, 2023

Grail and Galleri Competitive 2023-08-10.pdf

Hello team, Please find our competitive social listening snapshot below for 8/4 - 8/10.

Grail, Galleri, and Illumina

Companies We Follow

August 3, 2023

Grail and Galleri Competitive 2023-08-03.pdf

Hello team, Please find our competitive social listening snapshot below for 7/28-8/3.

Grail, Galleri, and Illumina

  • Our share of voice was 28%.
  • The SF Chronicle published a story about the Galleri test, which helped San Francisco rapper Berner detect colon cancer early. The article includes commentary from several industry experts who are wary of overtesting and caution against the widespread prescription of the test.
  • Grail: The National Medical Association tweeted about the “Disparities in Cancer: Screening, Diagnosis, and Treatment” presentation at, featuring contributions from Grail, BeiGene, the American Cancer Society, and the R. Frank Jones Urological Society. Grail’s president, Josh Offman, ****was interviewed by Buck Joffrey on the Sapio podcast to discuss MCED technology and the Galleri test.
  • Illumina is mentioned in several legal discussions:
    • BioSpace reports on the dismissal of litigation between Illumina and Guardant, as well as their new commercial partnership.
    • The Spectator reported on the congresses’ call for Lina Khan’s resignation. Darrell Issa, an opposing California Congressman, commented on the story: “Destroying the medical breakthrough that Illumina and Grail are trying to offer for the reasons she has stated could be the biggest mistake a federal regulator has ever made.”
    • The Open Markets Institute issues an amicus brief on the Illumina-FTC case, and asks the courts to deny any further petitions for review.
  • Galleri Classic is mentioned in the caption of a photo featuring Rocco Mediate, a previous participant of the Galleri Classic.

Companies We Follow

July 28, 2023

Grail and Galleri Competitive.pdf

Hello team, Please find our competitive social listening snapshot below for 7/21 - 7/27.

Grail, Galleri, and Illumina

  • Our share of voice was 53%.
  • The Galleri test is mentioned globally and in the UK:
    • A study evaluating the psychological impact of the Galleri test, as part of the NHS-Galleri trial, is published.
    • Jeremy Hunt, the UK’s Chancellor of the Exchequer, advocates for cancer research in an article on the Daily Mail, amidst his own battle with the disease. The article mentions the NHS-Galleri trial and the Galleri test, stating that “the Galleri test has already been successfully trialled in patients with symptoms, and can even tell doctors where in the body the tumor originated.”
    • A commenter in a Reddit discussion about blood cancer tests mentions the Galleri test, while also noting the potential for false positives across multiple cancer early detection tests in general.
  • Grail is discussed within the medical and technology industries:
    • LabPulse has covered the recent joint study with Mayo Clinic, titled “Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers”. The study is also being promoted by an HCP on Twitter.
    • A VC publishes a byline on Readwrite about innovations and benefits in digital biology, citing Grail’s use of digital biology tools to transform early cancer detection.
  • Fortune has published an in-depth article about the FTC-Illumina case, which focuses on a leadership angle including the proxy fight with Carl Icahn and the removal of Illumina executives. Meanwhile, a legal blog has covered the €432 million fine imposed on Illumina by the EU for acquiring Grail without the commission’s approval.

Companies We Follow

  • The Wisconsin State Journal covers Exact Sciences’ plan to seek approval for its Cologuard 2.0 blood test, and also mentions the Cologuard Classic. The company’s chief medical officer for screening is interviewed by Katie Couric Media to explain the digestion process in an educational article for patients.
  • Guardant Health’s Guardant 360 test is recommended by a user on Reddit on r/CancerFamilySupport in a discussion about lung cancer. Guardant Health’s founder participates in a Q&A for Fast Company about the future of blood-based cancer testing.
  • Natera shares a video on Facebook for day, highlighting a patient story. A patient on Reddit recommends Natera’s genetic testing.
  • Invitae’s genetic testing is reviewed in an article on xcode life, “Invitae Genetic Testing: What You Should Know Before Buying”.
  • Ioniq Sciences recognizes Utah Gov. Spencer J. Cox in an Instagram post for working with the company to improve MCED and “ensure it doesn’t limit competition and innovation”.

July 20, 2023

Grail and Galleri Competitive.pdf

Hello team, Please find our competitive social listening snapshot below for 7/14 - 7/20.

Grail, Galleri, and Illumina

  • Our share of voice was 66%.
  • The Galleri test is discussed by entrepreneurs, investors, HCPs, providers, and the NHS:
    • Angel investor and entrepreneur Jason Calacanis Tweets about taking the Galleri test—asking his followers if anyone else has taken the test and what they think about its cost. Some comments from fellow investors and technologists question the test’s accuracy, but overall support the test for advancing MCED.
    • Actor Orlando Bloom is featured patient in a video from provider Next Health, promoting their Executive Physical program. The Galleri test is included as part of the program and listed in the video’s description.
    • Another provider on Instagram, Cancercom_, promotes the Galleri test in an educational carousel post.
    • CGA-IGC publishes a podcast featuring Jordan Karlitz, MD, and Whitney Jones, MD from Grail about MCED and the Galleri test.
    • A blog post resurfaces the erroneous Galleri Test result letters story from June.
    • The NHS’ Genomics Education Programme publishes a blog post, highlighting results from the SYMPLIFY study.
  • Grail and Illumina in the news:
    • The UK’s Health and Social Care Committee airs a “Future of Cancer Detection” evidence session, shared in a Tweet. Grail’s Sara Hiom, VP, NHS Implementation & External Affairs, participates in the session. The BBC includes the session in a news roundup, and The Independent reports on it.
    • STAT publishes a story about three female sales executives suing Grail for harassment and and retaliation, with Illumina’s acquisition of Grail also mentioned in the story.

Companies We Follow

  • Exact Sciences publishes a promotional video on Facebook, highlighting its commitment to advancing MCED. In an article on Healthcare Digital, Exact Sciences’ breast cancer research shows that additional testing can reduce unnecessary appointments by 41% with the Oncotype DX test.
  • Fast Company interviews Guardant Health’s co-founder and co-CEO to discuss AI and ML in MCED and the company’s Infinity platform. Katie Couric Media reports on liquid biopsies, mentioning the Guardant360 CDx test.
  • Natera shares educational content on Facebook about bladder cancer. The company wins a favorable ruling in CareDx false advertising lawsuit, covered in Bloomberg.
  • Invitae promotes a patient story on Facebook, highlighting the role genetic testing plays in discovering the underlying causes of cardiomyopathy.
  • Ioniq Sciences received no mentions over the past week.

July 13, 2023

Grail and Galleri Competitive.pdf

Hello team, Please find our competitive social listening snapshot below for 7/7 - 7/13.

Grail, Galleri, and Illumina

  • Our share of voice was 95% over the last 7 days compared to companies we follow.
  • News of Illumina being fined $475M for acquiring Grail without the EU’s regulatory approval is the key conversation driver:
    • Mainstream media and industry press:
      • The Associated Press reported on the story from all sides, including commentary from an EU antitrust Commissioner and a statement from Illumina appealing the fine. The ongoing FTC-Illumina case is also mentioned, alongside the government agency’s other efforts to control acquisitions such as Microsoft’s purchase of Activision Blizzard.
      • CNBC discusses the finances in-depth, with commentary from an Illumina spokesperson: “Illumina has already put aside $453 million to cover a potential maximum fine of 10% of turnover”. Additionally, the article looks at Illumina’s strategy in navigating fees, and the support it has received from Republican lawmakers to increase availability of cancer testing with the merger.
      • Bloomberg Business, WSJ, and Forbes also cover the news, discussing the financial impacts of the fine.
    • Influencers and social discussions:
      • EU antitrust Commissioner Margrethe Vestager tweets an infographic outlining the timeline of events.
      • A software development influencer in Silicon Valley tweets CNBC’s story.
  • The Galleri test continues to be promoted by HCPs, patients, and providers:
    • An HCP for the NHS promotes several MCEDs in a tweet mentioning Galleri, Exact Sciences’ CancerSEEK, and Delphi’s test.
    • An HCP on Instagram promotes an “executive physical” for busy individuals, including the Galleri test as part of the package.
    • A patient and the founder of Drink Iconic (clean protein coffee products) shares his positive experience using the Galleri test on Instagram in a series of promotional posts (1, 2).
    • Victor Men’s Health shares a podcast interview on Instagram, featuring Dr. Whitney Jones, Grail’s Senior Medical Director, discussing MCED.

Companies We Follow

  • Exact Sciences is promoted by Katie Couric in a high-production video shared to Instagram, featuring in an inside look at the company’s lab and its scientists. The company invests in local affordable housing initiatives. A financial researcher promotes Exact Sciences in a tweet.
  • Guardant Health is mentioned in a tweet during the HLC Expo. In the tweet, HLC awards Ami Bera, M.D., the Champion of Healthcare Innovation Award.
  • A breast cancer patient on Instagram mentions Natera’s Signatera test, discussing MCED testing broadly and the role it plays in overall cancer treatment.
  • On YouTube, a provider mentions Invitae’s genetic testing as part of her services offered to patients. On Instagram, a patient with Hypermobile Ehlers Danlos Syndrome recommends Invitae’s genetic testing to help detect such conditions.
  • Ioniq Sciences has been awarded the Best Diagnostic Tech Solution of the year 2023 at the Medtech Breakthrough Awards. The company promotes on Facebook.

June 29, 2023

2023-06-29 Grail and Galleri Competitive Overview.pdf

Hello team, Please find our competitive social listening snapshot below for 6/23 - 6/29.

Grail, Galleri, and Illumina

Companies We Follow

June 22, 2023

2023-06-22 Grail and Galleri Competitive Overview.pdf

Hello team, Please find our competitive social listening snapshot below for 6/16 - 6/22.

Grail, Galleri, and Illumina

Companies We Follow

  • Exact Sciences promotes BLUE-C pivotal trial results on Facebook and Twitter, demonstrating 95% sensitivity for colorectal cancer at 91% specificity, with its next-gen Cologuard test. Medical Device Network, STAT, and Healio publish news stories. Baylor Scott & White Health launches an MCED program in partnership with Exact Sciences; its Director of Oncology Tweets the announcement.
  • Guardant Health supports National Black Family Cancer Awareness Week in a Tweet. The company’s Chief Medical Officer is featured in a video on SurvivorNet about cancer screening.
  • Natera promotes prenatal genetic screening in an educational post on Facebook. The Signatera test is mentioned as part of a new report on GI Cancer: “Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases.”
  • Invitae is featured in a broadcast segment on Midday Maryland (aired on WMAR 2, a local ABC affiliate). Invitae’s own Caroline Yost is interviewed.
  • Ioniq Sciences recognizes one of its young researchers on Instagram and Facebook as she gets accepted to attend Duke Medical School.

June 15, 2023

2023-06-15 Grail and Galleri Competitive Dashboard.pdf

Hello team, please find below our competitive social listening snapshot for 6/9 - 6/15.

Grail, Galleri, and Illumina

  • Our share of voice was 87%. HCPs, providers, organizations, media, and individuals are discussing the Galleri Test:
    • The media and influencers continue to cover the erroneous Galleri Test result letters. NYT Health and Breitbart have published new stories. Tech influencer John Nosta shared last week’s article from Ars Technica.
    • Dr. Joel Kahn mentions the Galleri Test in a Tweet, referencing his late mother: “Patients ask me if the @galleritest for cancer screening is worth $1000? Ask my MIL if she could answer. Health is priceless. Miss her.”
    • Other sources provide more comprehensive coverage of the Galleri Test in informational video content, such as Dr. Brad Stanfield on YouTube (28k views) and Parcham Classes on Instagram.
  • VA Research has announced a partnership with Grail on Twitter, which will add 10 new testing sites in Pennsylvania. Check out their tweet here.
  • The NHS-Galleri trial (SYMPLIFY) continues to be covered by media globally, with a YouTube video from The News Minute, a photo from the trial site shared on Twitter by the Greater Manchester Integrated Care Partnership, and an Instagram post from PET (Progress Educational Trust) promoting the study.
  • Rep. Darrell Issa discusses the FTC-Illumina case on Fox Business (Video Tweet). He expresses support for Grail and opposition to Lina Khan. USA Today and Barron’s cover the resignation of CEO Francis deSouza.

Companies We Follow

  • Exact Sciences sponsors the American Family Insurance Championship PGA Tour, which is promoted throughout Wisconsin by the Make-A-Wish foundation and Leah Doherty, a sports and news reporter for NBC15. The company has also partnered with Katie Couric on a new educational series called “The Exact Science Of”, featuring interviews with Exact Sciences experts.
  • A Guardant Health investor is promoted on Twitter as a speaker for the upcoming Slush 2023 conference. Guardant promotes the Guardant Infinity platform on Twitter.
  • A Natera patient celebrates becoming cancer-free on Instagram after confirming the results from taking a Signatera test. Natera has been recognized as a Best Workplace in Texas™ 2023 on Twitter.
  • Invitae recalls its previous support for increasing the accessibility of genetic testing. This is in celebration of the 10-year anniversary of AMP v Myriad, as posted on Facebook.
  • Ioniq Sciences promoted a podcast episode on Facebook featuring an interview with its CEO, who discussed the use of bioimpedance-based technology for early detection of cancer.

June 8, 2023

2023-06-08 Grail and Galleri Competitive Dashboard.pdf

Hello team, Please find our competitive social listening snapshot below for 6/2 - 6/8.

Grail, Galleri, and Illumina

  • Our share of voice increased by 25%, representing 95% share of voice over the last 7 days compared to companies we follow.
  • The erroneous Galleri Test result letters that were recently sent to patients is discussed widely by US media:
    • Top Tier:
      • Articles from The New York Times and Wall Street Journal focus on the software vendor issue with PWNHealth. The journalists mention both Grail and Illumina, referencing the ongoing FTC-Illumina case. The related Tweet from the NYT receives 262K impressions.
      • Financial Times (UK) also covers the story but from an insurance provider angle, interviewing both MassMutual and Principal who mention reviewing or pausing their current trial relationships with Grail.
      • Reuters briefly covers the news, referencing the ongoing FTC-Illumina case.
      • CBS News Moneywatch includes commentary from a Grail spokesperson, with the article naming PWNHealth as the culprit.
    • Broadcast:
      • CBS 8 San Diego covers the story from a human error/technology angle.
      • ABC 13News Now ties their story into the partnerships between Grail and local fire departments. Grail and Illumina are mentioned in both segments.
      • ABC7 Chicago focuses on the software vendor issue with PWNHealth.
    • Influencers:
      • An HCP Oncologist responds to the story with “This is horrendous” on Twitter.
      • A technology influencer shares a Tweet linking to coverage from Ars Technica. The Ars Technica article covers both the software vendor and insurance provider issues.
    • Other coverage:
      • The Deep Dive (Canada) covers the story on YouTube.
      • WebMD publishes a brief article, referencing the NYT piece.
  • The NHS-Galleri trial (SYMPLIFY) is covered by media in the UK with positive sentiment:
    • ITV News and Channel 4 News both cover the Galleri-NHS trial in positive broadcast segments, positioning MCED as a solution to speeding up the cancer screening process. The ITV News segment begins with an emotional patient death story.
    • The Independent includes commentary from NHS and the University of Oxford spokespeople.
  • Galleri receives more international attention:
    • Prag News (India) positions the Galleri Test as a “promising” early cancer detection solution in a news segment on YouTube.
    • A YouTube Shorts clip (India) explains the Galleri Test. The clip has 1.4k views in just under a day. YouTube Shorts may be a platform worth tracking, as it attempts to compete with other short-form video platforms like TikTok and Instagram Reels.
  • Reuters covers Illumina’s appeal of the recent FTC order to divest Grail.
  • Galleri Classic was mentioned in a few “top golfers to watch” articles (1, 2).

Companies We Follow

June 1, 2023

2023-06-01 Grail and Galleri Competitive Dashboard.pdf

Hello team, Please find our competitive social listening snapshot below for 5/26 - 6/1.

Grail, Galleri, and Illumina

Companies We Follow

  • Exact Sciences’ Oncotype DX test is mentioned in a French interview about breast cancer. The journalist shares the story on Twitter. The company promotes its “Great Place to Work” certification on Facebook.
  • Guardant Health’s Guardant360 CDx CGP blood test is approved in Singapore. The company is promoted as a Cancer Survivors Day sponsor on Twitter.
  • Natera promotes its ****3 EMPOWER-Lung 1 and CIRCULATE-Japan studies at on Twitter.
  • Data from an Invitae-Stanford study on renal cancer is shared on Twitter during an presentation. An upcoming Invitae presentation about data and interoperability in healthcare is promoted on Twitter ahead of the Practising Law Institute’s Health Care Technology 2023 event.
  • Ioniq Sciences publishes a press release announcing its upcoming presentation about early cancer detection at the LD Micro Invitational XIII.

May 25, 2023

2023-05-25 Grail and Galleri Competitive Dashboard.pdf

Hello team, Please find our competitive social listening snapshot below for 5/19 - 5/25.

Grail, Galleri, and Illumina

Companies We Follow

May 18, 2023

2023-05-18 Grail and Galleri Competitive Dashboard.pdf

Hello team, Please find our competitive social listening snapshot below for 5/12 - 5/18. This week we added stakeholder share of voice and expanded language demographics to show a breakdown of users.

Grail, Galleri, and Illumina

  • Our share of voice was 16%.
  • HCPs, providers, organizations, media, and individuals are discussing the Galleri test:
    • Bloomberg Business featured the Galleri Test in a newsletter over the weekend. The article had a neutral sentiment and included interviews with experts from the Scripps Research Translational Institute and the American Cancer Society. Both experts stressed the importance of data in determining the efficacy and future of MCED tests. While the journalist mentioned the NHS-Galleri trial, she also pointed out that the Galleri test is not FDA-approved.
    • True Women’s Health promotes the Galleri test in a series of Instagram posts (1, 2).
    • The Greater Manchester Cancer Alliance announces a continuation of the NHS-Galleri Trial on Twitter to participants.
    • Provider Peak Performance and Prevention partners with Puget Sound Fire of Washington State to provide the Galleri Test, sharing a photo on Instagram.
  • A conservative journalist writes a story for The Spectator about the Illumina-FTC case, pointing the finger at Lina Kahn for “undermining Biden’s cancer moonshot”. He also mentions the Illumina-FTC case in a series of Tweets. Carl Icahn’s attempt to unseat Illumina’s CEO is discussed on Barron’s.
  • The Galleri Classic is mentioned in an article about Golfer John Daly.

Companies We Follow

May 11, 2023

2023-05-11 Grail and Galleri Competitive Dashboard.pdf

Hello team, Please find our competitive social listening snapshot below for 5/5 - 5/11.

Grail, Galleri, and Illumina

  • Our share of voice was 55%.
  • HCPs, providers, organizations, and individuals are discussing the Galleri test:
    • Dr. Joel Kahn shares an article about World Ovarian Cancer Day and early detection, mentioning the Galleri Test as a solution in this tweet.
    • The Rewind Anti-Aging of Miami Wellness clinic promotes the Galleri test in a series of Instagram posts (1, 2, 3).
    • The NHS and Greater Manchester Cancer Alliance promote the NHS-Galleri Trial on Twitter (1, 2), thanking participants. An HCP shares a photo from the trial site here.
    • The Georgetown Fire Department shares broadcast coverage of its partnership with Galleri on Twitter here, and an article about it is published online here.
    • The Galleri test is mentioned in several posts about cancer on Reddit (1, 2, 3).
    • The MemorialCare Long Beach Medical Center discusses the PATHFINDER 2 study in a broadcast segment on Long Beach Local News.
  • The Ilumina-FTC trial is mentioned in an op-ed on the Hill about antitrust lawsuits, as well as in a story on Bloomberg. Medtech Insight discusses the clash between Carl Icahn and Illumina.
  • David Toms is mentioned as winner of the Galleri Classic in an article on Canadian Sports Scene.

Companies We Follow

  • Exact Sciences is mentioned as a partner by the Forward Madison FC soccer team on Facebook. Opportunity Development Centers acknowledges the company as a sponsor of its Opportunity for Hope cause, and The American College of Healthcare Executives shares an additional sponsorship post for. In response to a tweet from the company announcing its presence at, a stage 3 survivor thanks Exact Sciences.
  • An HCP mentioned Invitae on Twitter in reference to its PREVGEN study. Another HCP shared a slide from the live presentation at.
  • Guardant Health published an Op-Ed on the pathologist about colorectal cancer, which was shared on Twitter. You can find the tweet here.
  • Natera promotes its Renasight test on Twitter.
  • Ioniq Sciences acknowledges one of its scientific advisors for National Cancer Research Month in a post on Instagram.

May 5, 2023

Hello team, Please find our competitive social listening snapshot below for 4/28 - 5/4.

Grail, Galleri, and Illumina

Companies We Follow

April 20, 2023

Hello team, Please find linked below our competitive social listening snapshot for 4/14 - 4/20.

Before compiling this week’s report, we revised our search terms and keywords in our social listening software. This was done to produce more accurate and relevant results across all social networks. We specifically focused on increasing the pickup of discussions from owned social accounts, such as Grail, Galleri, and competitors’ accounts. Furthermore, we reduced the number of verbatim press release pickups such as market reports and financial markets news.

Due to the adjustments mentioned above, the week-over-week comparison data in this week’s report shows greater differences than usual. Going forward, the comparisons will be more consistent.

Key findings include:

Graph View

Backlinks

  • No backlinks found